Table 2.
Patients/treatment characteristics and late toxicities.
| Pt. No. | Node No. | EBRT(Gy) | Nodal BT (Gy/Fx) | D90% in Total EQD2 (Gy) | D95% in Total EQD2 (Gy) | SBD0.1cc in Total EQD2 (Gy) | SBD1cc in Total EQD2 (Gy) | Pelvic Control | Grade 2–4 toxicity | F/U (month) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 50.4 | 6Gy/1Fx | 54.9 | 54.3 | 54.2 | 51.8 | CR | None | 56 |
| 2 | 6Gy/1Fx | 54.7 | 54.1 | 61.1 | 55.6 | CR | ||||
| 2 | 3 | 50 | 12Gy/2Fx | 71.7 | 68.3 | 65.2 | 58.3 | CR | None | 54 |
| 3 | 4 | 50.4 | 6Gy/1Fx | 61.4 | 59.7 | 52 | 51.2 | CR | Gr3 bladder bleeding | 42 |
| 4 | 5 | 50.4 | 18Gy/3Fx | 81 | 76.1 | 66.8 | 61.9 | PR | None | 31 |
| 5 | 6 | 50.4 | 18Gy/3Fx | 75.8 | 72.6 | 71.2 | 65.5 | PD | None | 29 |
| 6 | 7 | 50.4 | 6Gy/1Fx | 60.1 | 58.9 | 53 | 51.8 | CR | None | 9 |
| 8 | 18Gy/3Fx | 67.1 | 64.7 | 61 | 57.4 | CR | ||||
| 7 | 9 | 50.4 | 6Gy/1Fx | 58.9 | 58 | 54.2 | 52.4 | CR | Gr2 pubic bone fracture | 27 |
| 8 | 10 | 50.4 | 6Gy/1Fx | 64.6 | 62.7 | 51 | 50.1 | CR | None | 26 |
| 9 | 11 | 50.4 | 6Gy/1Fx | 67 | 64.6 | 54.2 | 52.4 | CR | None | 26 |
| 12 | 6Gy/1Fx | 60.3 | 58.5 | 57.8 | 54 | CR | ||||
| 10 | 13 | 50 | 6Gy/1Fx | 60.7 | 58.4 | 68.4 | 60.8 | CR | None | 9 |
| 11 | 14 | 50.4 | 12Gy/2Fx | 66.6 | 65.6 | 59.4 | 55.3 | CR | None | 20 |
| 12 | 15 | 50.4 | 18Gy/3Fx | 73.6 | 70.2 | 74.2 | 65.2 | CR | None | 17 |
| 13 | 16 | 50.4 | 12Gy/2Fx | 67.9 | 66.7 | 62.5 | 58.1 | CR | None | 13 |
| 14 | 17 | 50.4 | 12Gy/2Fx | 69.7 | 65.7 | 60.9 | 58.1 | CR | None | 7 |
BT, Brachytherapy; CR, Complete response; EBRT, external beam radiotherapy; EQD2, Equivalent dose of 2 Gy; F/U, Follow-up; PR, Partial response; PD, Progression of disease; D90% and D95%, minimum dose delivered to 90% and 95% of the volume of the nodal planning target volume, respectively.